Company intelligence / Profile preview

Biobrás

Montes Claros, Minas Gerais, Brazilbiomm.com ↗

Ownership: Private
Development stage: Other

Overview

Biobrás was a pioneering Brazilian biopharma company, recognized as one of the world’s largest producers of insulin. It developed and patented recombinant human insulin technology and exported pharmaceutical products globally. In 2002, Novo Nordisk acquired a controlling stake in the company.

Therapeutic areas: Endocrinology
Modalities: ProteinRecombinant proteinSmall molecule
Industry: Pharma

Partnerships

Eli Lilly & Co. (joint venture for local production of animal insulin in Brazil during early years)

Beyond the preview

Go deeper on Biobrás.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biobrás.

Explore the full profile